Multilingual information regarding the proposed amendments to the International Health Regulations.
Discover more from James Roguski
Multilingual information regarding the proposed amendments to the International Health Regulations.
If you would like to help add to the content here, that would be very much appreciated. 310-619-3055 (Many thanks to Kathlyn for these translations)
Quick link to EVIDENCE: DontYouDare.INFO
Quick link to ACTIVIST TOOLBOX: StopTheWHO.com
ARABIC:
DUTCH
FRENCH
GERMAN
HINDI
JAPANESE
MANDARIN
The PDF below is a spectacular analysis of the proposed amendments to the International Health Regulations:
MALAY
PORTUGUESE
RUSSIAN
SPANISH
https://www.bitchute.com/video/8jQ1GpS553zB/
SWAHILI
This is the tenth article in this series.
WE ARE IN A SPIRITUAL WAR (motivation)
Multilingual information regarding the proposed amendments to the International Health Regulations.
by James Roguski
The old system is crumbling, and we must build its replacement quickly.
If you are fed up with the government, hospital, medical, pharmaceutical, media, industrial complex and would like to help build a holistic alternative to the WHO, then feel free to contact me directly anytime.
JamesRoguski.substack.com/about
JamesRoguski.substack.com/archive
310-619-3055
Multilingual information regarding the proposed amendments to the International Health Regulations.
Fantastic that you're doing this. Bravo.
From the WHO website:
"Today (4-22-22), WHO made a strong recommendation for nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospital admission, calling it the best therapeutic choice for high-risk patients to date. "Along with the strong recommendation for the use of nirmatrelvir and ritonavir, WHO has also updated its recommendation on remdesivir, another antiviral medicine."
"Previously, WHO had suggested against its use in all COVID-19 patients regardless of disease severity, due to the totality of the evidence at that time showing little or no effect on mortality. Following publication of new data from a clinical trial looking at the outcome of admission to hospital, WHO has updated its recommendation. WHO now suggests the use of remdesivir in mild or moderate COVID-19 patients who are at high risk of hospitalization."
As I always say, "You can't make this $h!t up." & "Follow the Money."
Thanks, James, thanks a lot.